Gilead’s Truvada Trumps Combivir In Rx Market Share For Therapy Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Gilead Sciences' combination antiretroviral therapy Truvada (emtricitabine/tenofovir) achieved a market-leading 18.7% of total prescriptions in the nucleoside reverse transcriptase inhibitor class during the third quarter, according to Gilead
You may also be interested in...
Gilead Truvada switch study
A study in treatment-experienced HIV patients suggests patients switching from GlaxoSmithKline's Combivir (lamivudine/zidovudine) to Gilead's Truvada (emtricitabine/tenofovir) achieve significantly more viral suppression, Gilead reports Nov. 17. In the Phase IV COMET (Combination of Efavirenz and Truvada) study, presented at the European AIDS Conference Nov. 17 in Dublin, 76% of switched patients had viral load below 50 copies/mL compared to 59% at baseline (p<0.001); efavirenz (Bristol-Myers Squibb's Sustiva) was the background therapy in the study. Gilead has been highlighting Truvada's building sales momentum. Combivir continued to be the market leading nucleoside reverse transcriptase inhibitor in the third quarter, but Truvada sales were up 32%, putting it at the number three slot for the NRTI class (Pharmaceutical Approvals Monthly November 2005, p. 5)...
Gilead Truvada switch study
A study in treatment-experienced HIV patients suggests patients switching from GlaxoSmithKline's Combivir (lamivudine/zidovudine) to Gilead's Truvada (emtricitabine/tenofovir) achieve significantly more viral suppression, Gilead reports Nov. 17. In the Phase IV COMET (Combination of Efavirenz and Truvada) study, presented at the European AIDS Conference Nov. 17 in Dublin, 76% of switched patients had viral load below 50 copies/mL compared to 59% at baseline (p<0.001); efavirenz (Bristol-Myers Squibb's Sustiva) was the background therapy in the study. Gilead has been highlighting Truvada's building sales momentum. Combivir continued to be the market leading nucleoside reverse transcriptase inhibitor in the third quarter, but Truvada sales were up 32%, putting it at the number three slot for the NRTI class (Pharmaceutical Approvals Monthly November 2005, p. 5)...
Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
Bristol/Gilead joint venture targets 2005 filing for fixed-dose HIV combo. A new brand name for the fixed-dose combination of Bristol’s Sustiva and Gilead’s Truvada is expected. Firms will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products”